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Abstract
For the generation of cell-based therapeutic products, it
would be preferable to avoid the use of animal-derived
components. Our study thus aimed at investigating the
possibility to replace foetal bovine serum (FBS) with
autologous serum (AS) for the engineering of cartilage
grafts using expanded human nasal chondrocytes (HNC).
HNC isolated from 7 donors were expanded in medium
containing 10% FBS or AS at different concentrations (2%,
5% and 10%) and cultured in pellets using serum-free
medium or in Hyaff®-11 meshes using medium containing
FBS or AS. Tissue forming capacity was assessed
histologically (Safranin O), immunohistochemically (type
II collagen) and biochemically (glycosaminoglycans –
GAG- and DNA). Differences among experimental groups
were assessed by Mann Whitney tests. HNC expanded
under the different serum conditions proliferated at
comparable rates and generated cartilaginous pellets with
similar histological appearance and amounts of GAG.
Tissues generated by HNC from different donors cultured
in Hyaff®-11 had variable quality, but the accumulated GAG
amounts were comparable among the different serum
conditions. Staining intensity for collagen type II was
consistent with GAG deposition. Among the different serum
conditions tested, the use of 2% AS resulted in the lowest
variability in the GAG contents of generated tissues. In
conclusion, a low percentage of AS can replace FBS both
during the expansion and differentiation of HNC and reduce
the variability in the quality of the resulting engineered
cartilage tissues.
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Introduction
Current clinical practice for the treatment of cartilaginous
defects created by trauma, tumor resection, or congenital
deformities in the nasal compartment consist on the
grafting of autologous cartilage. The main problems
associated with such approach are the difficulty to obtain
a sufficient amount of implant material and the donor-
site morbidity. Tissue engineering offers the possibility
of producing autologous cartilage in large quantity,
starting from a small tissue biopsy and thus with minimal
donor site morbidity. Monolayer expanded human nasal
chondrocytes cultured on different scaffolds have been
shown to generate grafts with clinically relevant size and
with biomechanical and biochemical properties
approaching those of native nasal cartilage (Farhadi et
al., 2006; Rotter et al., 2002). Moreover, Rotter et al. in
their study have not observed age-related difference in
the quality of the engineered tissues, thus opening the
possibility to apply such technique for a broad patient
group.
In the papers mentioned above, foetal bovine serum
(FBS) was used for the culture of human nasal
chondrocytes. However, the use of animal sera for the
generation of grafts for clinical use should be seriously
considered since such supplements carry the remote
possibility of prion or viral transmission and of immune
reaction against animal proteins. Substitution of animal
serum with autologous serum would address these issues
and bring human cartilage tissue engineering nearer to a
safe clinical application.
Several studies reported that human serum promotes
the growth of human chondrocytes at similar or superior
extent than FBS (Choi et al., 1980; Gruber et al., 1996;
Badrul et al., 2004; Chua et al., 2004; Tallheden et al.,
2005; Kamil et al., 2007; Chua et al., 2007). However
such studies focused primarily on the ability of
chondrocytes to proliferate in monolayer. Alexander et
al. were the first to evaluate the effects of human serum
on chondrogenesis of tissue-engineered human nasal
chondrocytes in 3D culture (Alexander et al., 2006). By
culturing human nasal chondrocytes in alginate beads, the
authors demonstrated that human serum resulted in
increased production of cartilaginous extracellular matrix
as compared to the FBS control group (Alexander et al.,
2006). However, for this study a pool of human sera was
used, therefore the obtained data are not directly applicable
to the engineering of autologous grafts intended for
reimplantation in humans, because of risks of transmission
of viral infection.
With the goal of defining clinically-applicable culture
conditions for the generation of autologous cell-based
chondrogenic grafts for repair of nasal cartilage, we
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determined the effect of autologous serum (AS) on
proliferation and post-expansion chondrogenic capacity
of human nasal chondrocytes (HNC). Effects of AS at
different concentrations (10%, 5% and 2%) were compared
to the standard culture condition using 10% FBS.
Materials and Methods
Sample collection
Nasal cartilage biopsies of about 100mg weight were
harvested from 7 donors (donor 1: 20 years, female; donor
2: 21 years, male; donor 3: 27 years, female; donor 4: 35
years, female; donor 5: 41 years, male; donor 6: 50 years,
female; donor 7: 65 years, male) undergoing routine
esthetical surgery in accordance with the Local Ethical
Committee. Blood (about 50 ml) withdrawn from each
patient was collected into serum tubes and incubated at
37°C water bath for one hour to induce its coagulation.
Clotted blood was then centrifuged at 3500 rpm for 15
min to separate the serum (about 25 ml).
Chondrocyte isolation and expansion
Cartilage tissues were minced in small pieces and digested
with 0.15% type II collagenase (10 mL solution/g tissue)
for 22 hours. The isolated chondrocytes were seeded at
104 cells/cm2 with basic medium (Dulbecco’s Eagle’s
Medium containing 4.5 mg/mL D-glucose, 0.1 mM
nonessential amino acids, 1 mM sodium pyruvate, 100 mM
HEPES buffer, 100 U/mL penicillin, 100 µg/mL
streptomycin and 0.29 mg/mL L-glutamate) additioned
with 10% of foetal bovine serum (FBS) or autologous
serum (AS) at different concentrations (2%, 5% and 10%)
and further supplemented with 1 ng/mL Transforming
Growth Factor β1 (TGFβ1) and 5 ng/mL Fibroblast
Growth Factor 2 (both from R&D Systems, 6 Minneapolis,
MN). This specific combination of growth factors was
previously shown to enhance human nasal chondrocyte
proliferation and post-expansion differentiation ability (Tay
et al., 2004).
Medium was changed twice a week. When cells were
subconfluent (P1), they were detached by sequential
treatment with 0.3% type II collagenase, followed by
0.05% trypsin/0.53mM EDTA, replated at 5x103 cells/cm2
and cultured until they reached one other time the
subconfluency (P2). Chondrocytes were subsequently
cultivated in pellets or in 3D scaffolds as described below
(see also Fig. 1).
Due to the limited amount of human serum obtained,
in some cases, it was not possible to culture HNC in pellets
or in scaffolds under all the AS conditions.
Pellet culture
To assess the chondrogenic capacity of HNC expanded
under the different serum conditions, cells were cultured
in pellet using a defined serum-free medium, as previously
described (Barbero et al., 2003).
Briefly, HNC were suspended in basic medium
supplemented with ITS+1 (Sigma Chemical, St. Louis,
MO), 0.1 mM ascorbic acid 2-phosphate, 1.25 mg/ml
Figure 1. Experimental design. For each donor, nasal chondrocytes were isolated from a cartilage biopsy and autologous
serum (AS) separated from blood sample. Chondrocytes were expanded in monolayer in medium containing 10%
foetal bovine serum (FBS) or AS at different concentrations (2%, 5% and 10%). Post expanded chondrocytes were
then induce to re-differentiate in pellets in serum-free medium or in Hyaff®-11 scaffolds in medium containing the
different types and percentages of serum.
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human serum albumin, 10-7 M dexamethasone and 10 ng/
mL TGFβ1. Aliquots of  5 x 105 cells/0.5 ml were
centrifuged at 1000 rpm for 2 minutes in 1.5 ml
polypropylene conical tubes (Sarstedt, Nümbrecht,
Germany) to form spherical pellets, which were placed
onto a 3D orbital shaker (Bioblock Scientific, Frenkendorf,
Switzerland) at 30 rpm. The medium was changed twice
per week. Pellets were cultured for 2 weeks and
subsequently processed for histological and biochemical
analysis as described below.
Culture on porous 3D scaffolds
To investigate how the use of autologous serum at different
concentrations could influence the HNC ability to generate
3D cartilaginous tissues using porous scaffolds, post-
expanded HNC were induced to re-differentiate in
esterified hyaluronic acid non-woven meshes (Hyaff®-11,
Fidia Advanced Biopolymers, Abano Terme, Italy), as
previously described (Farhadi et al., 2006). Briefly,
chondrocytes expanded with 10% FBS or AS at different
concentrations (2%, 5% and 10%) were seeded statically
on the scaffolds (6 mm diameter, 2 mm thick disks) at a
concentration of 4x106 cells/scaffold (corresponding to
7x104 cells/mm3). Resulting constructs were cultured for
4 weeks in basic medium supplemented with the same
serum condition used during expansion and further
additioned with 0.1 mM ascorbic acid, 10 mg/ml insulin
and 10 ng/ml Transforming Growth Factor-β3. Culture
medium was changed twice a week. The resulting
cartilaginous tissues were processed for histological and
biochemical analyses as described below. At difference
from the pellet cultures, serum was added for the culture
of HNC in Hyaff®-11, since its presence was preliminarily
observed to be required for chondrogenesis in a porous
scaffold, probably due to the relatively lower cell density
in such environment (data not published).
Analytical methods
Proliferation rate. Proliferation rate was calculated as the
ratio of log2(N/N0) to T, where N0 and N are the numbers
of cells respectively at the beginning and  at the end of the
expansion phase, log2(N/N0) is the number of cell
doublings, and T is the time required for the expansion.
Histological and immunohistochemical analysis. Pellets
and constructs were fixed in 4% formalin for 24h at 4°C,
embedded in paraffin, cross-sectioned (5µm thick) and
stained with Safranin O for sulphated glycosaminoglycans
(GAG). The “Bern Score” was used to visually score the
quality of pellets (Grogan et al., 2006). This assessment
takes into consideration (i) the uniformity and intensity of
Safranin-O stain, (ii) the distance between cells and amount
of matrix produced, and (iii) the cell morphology found
within sections. Sections were also processed for
immunohistochemistry as previously described (Grogan
et al., 2003). Briefly, after pre-treatment with 1 mg/ml
chondroitinase, sections were incubated with monoclonal
primary antibodies for type II collagen (II-II6B3,
Hybridoma Bank, University of Iowa, USA) for 1 h. The
slides were then incubated with a biotinylated goat anti-
mouse secondary antibody for 35 min followed by
StrABC/AP for 45 min (DAKO, Denmark). Bound
antibodies were made visible by means of New Fuchsin/
Naphthol AS-BI substrate (Sigma Chemical Co.,
Switzerland).
Biochemical analysis. For determination of GAG and
DNA, pellets and constructs were digested with proteinase
K (0.5 mL of 1mg/mL protease K in 50mM Tris with 1mM
EDTA, 1 mM iodoacetamide and 10 µg/mL pepstatin-A)
for 15 hours at 56°C. GAG amounts were measured
spectrophotometrically after reaction with dimethyl-
methylene blue (Farndale et al., 1986), with chondroitin
sulfate as a standard. DNA was measured spectro-
fluorometrically using the CyQuant cell proliferation assay
Kit (Molecular Probes, Eugene, OR), with calf thymus
DNA as a standard (Handley et al., 1995). GAG contents
are reported as GAG/DNA.
Statistical analysis. All values are presented as mean ±
standard error of measurements from independent
experiments with cells from a minimum of 4 different
donors. The coefficient of variation (i.e., standard deviation
as a percentage of the mean), was used to assess the
variability of GAG contents in tissues generated under the
different serum conditions. Differences among
experimental groups were assessed by Mann Whitney tests,
and considered statistically significant with p<0.05.
Correlation analysis was performed using Pearson’s tests.
Results
Proliferation rate of human nasal chondrocytes
HNC expanded in medium containing FBS or AS at the
different concentrations tested exhibited a similar elongated
fibroblastic morphology (data not shown). HNC
proliferated at comparable rates in the different serum
conditions (Fig. 2), with no statistically significant
differences among groups. HNC cultured in the different
Figure 2.  Proliferation rate (number of doublings/day)
of HNC expanded in medium containing 10% foetal
bovine serum (FBS) or autologous serum (AS) at
different concentrations (2%, 5% and 10%). Values are
mean ± standard error of the mean (SEM) of
measurements obtained from 7 independent
experiments. Differences in proliferation rates between
AS and FBS were statistically not significant (p values
are: 0.31, 0.29 and 0.24 for 2%, 5% and 10% AS).
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Figure 3.  Safranin O staining of representative pellets generated by HNC expanded under the different serum
conditions (reported on the top of the panel). During pellet culture, a serum-free medium containing chondrogenic
factors was used (see Materials and Methods section). Due to a limited amount of HNC and/or autologous serum,
for each donor it was not possible to have the full set of conditions, as evidenced by the empty squares in the panel.
Bar = 100 µm.
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Figure 4. Sulphated glycosaminoglycan (GAG) content of the pellets (A) or constructs (B), reported as µg GAG/µg
DNA. Values are mean ± SEM of measurements obtained from at least 4 independent experiments. Differences in
GAG contents between autologous serum (AS) and foetal bovine serum (FBS) were statistically not significant
either for HNC cultured in pellets (p values: 0.32, 0.37 and 0.50 respectively for 2% AS, 5% AS and 10% AS) and
in scaffolds (p values: 0.441, 0.31 and 0.40 respectively for 2% AS, 5% AS and 10% AS).
Figure 5. Safranin O and collagen type II stainings of representative pellets (A) and construct (B) generated by HNC
from donor 3 and donor 4 cultured with 2% autologous serum (AS) or 10% foetal bovine serum (FBS). Bars = 100
µm
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Figure 6. Safranin O staining of representative constructs generated by HNC expanded under the different serum
conditions (reported on the top of the panel). During construct culture, the same medium used for cell expansion
(i.e., using the corresponding serum condition) was further supplemented with chondrogenic factors (see Materials
and Methods section). Due to a limited amount of HNC and/or autologous serum, for each donor it was not possible
to have the full set of conditions, as evidenced by the empty squares in the panel. Bar = 100 µm.
7F. Wolf et al.                                                                                                                Nasal cartilage engineering with autologous serum
conditions underwent a minimum of 8 population
doublings in two weeks.
Post-expansion chondrogenic capacity in pellets
After 2 weeks’ pellet culture, post-expanded HNC
generated cartilaginous tissues whose quality largely
differed among the different donors as evidenced by the
different intensity of staining for GAG (Fig. 3). However,
no systematic differences in tissue quality were observed
among pellets generated by HNC expanded with FBS or
AS at the different concentrations tested. Visual
histological grading of the cartilaginous quality of the
pellets according to the “Bern Score” resulted in similar
values for pellets generated by HNC expanded with 2%
AS, 5% AS, 10% AS or 10% FBS (respectively 6.2±1.2,
6.4±1.0, 5.3±1.3 and 5.6±0.7). Staining appeared to be less
intense in pellets generated from the oldest donors as
compared to the others, although age-dependent variations
in the chondrogenic capacity or in the response to the
different serum conditions were beyond the scope of our
study.
Biochemical analysis quantitatively confirmed (i) a
general large donor-to-donor variability in chondrogenic
capacity, evidenced by the large standard error in the GAG
content of pellets, and (ii) the similar amount of GAG
contents (p>0.05) between pellets generated by HNC
expanded in the different serum conditions (Fig. 4A).
Histological and biochemical findings were consistent,
since a statistically significant correlation was found
between the GAG/DNA content and the “Bern Score” of
pellets (p<0.001). Interestingly, a reduced percentage of
AS used during the expansion resulted in reduced
variability in the GAG contents of pellets, with coefficients
of variation (i.e., standard deviation/mean) of 0.49, 0.65,
1.19 and 0.78 respectively for 2% AS, 5% AS, 10% AS
and 10% FBS.
Pellets that were more intensely stained for Safranin
O were generally also more intensely stained for collagen
type II, as assessed by immunohistochemical staining (Fig.
5A) and consistently with a previous study using the same
model (Barbero et al., 2004).
Tissue-forming capacity in 3D scaffolds
After 4 weeks of culture in scaffolds, the resulting tissues
had quality that largely differed between the different
donors. Tissues generated by 4 out of 7 donors (donors 1,
2, 4 and 5) had generally a hyaline-like appearance, with
regions intensely stained for GAG. Cells derived from the
other donors produced tissues negatively stained for GAG,
with fibroblastic cell morphology (donors 3 and 6) or large
areas of necrosis (donor 7). Again, no systematic
differences in tissue quality were observed between
constructs generated by HNC cultured under the different
serum conditions (Fig. 6). In agreement with the
histological observations, biochemical analysis
demonstrated (i) a generally lower chondrogenesis as
compared to pellet cultures, (ii) large donor-to-donor
variability in the GAG contents and (iii) similar amounts
of GAG contents (p>0.05) in constructs generated in the
different serum conditions (Fig. 4B). A positive correlation
(p<0.001) was demonstrated between the GAG/DNA
contents of scaffold-based constructs and of pellets
generated by cells of the corresponding donors and culture
conditions. Similarly to the redifferentiation in pellets, the
use of the lowest AS percentage during the culture in
scaffold resulted in the lowest variability in the GAG
contents of tissues, with coefficients of variations of 0.63,
1.00, 0.89 and 0.77 respectively for 2% AS, 5% AS, 10%
AS and 10% FBS.
Constructs that were more intensely stained for
Safranin O were generally also more intensely stained for
collagen type II, as assessed by immunohistochemical
staining (Fig. 5B).
Discussion
In the present study we demonstrated that human nasal
chondrocytes (HNC) cultured in medium containing
autologous serum (AS), even at low percentage (i.e., 2%),
exhibit similar proliferation rates and capacity to re-
differentiate and generate cartilaginous tissue than HNC
cultured with medium supplemented with 10% foetal
bovine serum (FBS).
Previous studies comparing chondrocyte growth with
human serum and FBS generally reported superior
proliferation rate of chondrocytes in human serum (Choi
et al., 1980; Gruber et al. 1996, Chua et al., 2004; Tallheden
et al., 2005; Chua et al., 2007). The discrepancy to our
results could be due to a number of different factors,
including the origin of the chondrocytes, the presence of
additional growth factors in the culture medium and the
origin of the serum (autologous or a pool of human sera).
In any case, considering only 2 passages of cell expansion
(i.e., about 8 doublings) and a previously determined yield
of about 3.5x106 cells/gram of cartilage tissue (Tay et al.,
2004), a normal size biopsy (i.e., about 100 mg) would
allow (using the conditions of the present study, namely a
scaffold thickness of 2 mm and a cell density of 7x104
cells/mm3) to engineer a graft of about 6 cm2 size.
In order to assess whether the chondrogenic capacity
of HNC could have been influenced by the different serum
conditions used during the expansion phase, HNC were
then cultured in macromass pellet cultures. Our results
indicated that chondrocytes expanded with FBS and AS
(even when used at the lowest concentration) exhibited
comparable chondrogenic capacity. Similarly, human
articular chondrocytes expanded with different
concentration of a pool of human sera (e.g.: 1%, 5% and
10%) have been shown to generate pellets of comparable
quality (Francioli et al., 2007).
The influence of autologous serum in modulating the
capacity of HNC to generate cartilaginous tissues was also
assessed for the culture in 3D porous scaffolds. HNC
cultured in Hyaff®-11 meshes with FBS or with the
different AS concentration produced tissues with
comparable quality and GAG contents. In a previous study,
Alexander et al. (Alexander et al., 2006) used different
concentrations of a pool of human sera for the expansion
and the 3D differentiation of nasal chondrocytes in alginate
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beads. They reported that chondrogenesis of HNC was
higher with 10% AS as compared to 10% FBS and 2%
AS. The difference between these results and our finding
may be related to the different type of human serum used
(autologous vs. pooled human serum), different 3D culture
conditions (scaffold vs. gel) and/or duration of the culture
(2 vs. 4 weeks).
The use of AS at low percentages would be favourable
not only to reduce the volume of blood from the patient
but also to reduce the dependence of the culture to a non-
standardized factor. Indeed, we have demonstrated that a
reduced concentration of AS in the culture medium
supported a reduced variability in the accumulation of
GAG. Despite the improved reproducibility of the result,
it should be pointed out that still great differences in the
quality of engineered tissue were found even when 2% of
AS was used, potentially effecting the outcome of cartilage
repair approaches based on grafting of engineered tissues.
Thus, our findings point out the importance of the
identification of means of predicting and possibly
overcoming biological variations in different chondrocyte
preparations (Dell’Accio et al., 2001; Grogan et al., 2007).
In our study, specific growth factors in addition to AS
or FBS have been used during the phase of monolayer
expansion to enhance the extent of cell proliferation of
HNC and during the phase of 3D culture to induce cells to
re-differentiate and produce cartilage specific matrix.
Therefore, this work could be extended by testing
autologous platelet-rich plasma, previously used to
stimulate the proliferation and differentiation of
chondrocytes (Gaissmaier et al., 2005; Akeda et al., 2006),
to replace both serum and growth factors.
In conclusion, a low percentage of AS can be used for
both the expansion and differentiation of HNC, supporting
the formation of cartilaginous tissues in the absence of
FBS and thus possibly facilitating clinical translation of
engineered cartilage constructs for nasal reconstruction.
Moreover, considering the recent reports on the
responsiveness of HNC to joint-specific regimes of
physical loading (Candrian et al., 2008), the relevance of
the present study could be extended toward the safe culture
of HNC for the treatment of articular cartilage defects.
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Discussion with Reviewers
S. Grad: The chondrogenic capacity of cells from different
donors is known to vary substantially. However, although
the outcome of the pellet and scaffold cultures cannot be
directly compared due to different culture conditions and
times, it may be expected that identical cell populations
would behave similarly in pellet and scaffold culture. This
does not seem to be the case for all donors. There are even
cell populations that stain more intensely in scaffolds than
in pellet culture, although generally there is a trend for
more matrix accumulation in the pellets. Thus the
chondrogenic capacity appears not only to depend on the
cell population but also on the culture conditions, which
further complicates the identification of markers of in vitro
chondrogenic capacity. What might be the reason(s) for
this different behaviour in different culture, and what are
the consequences from the authors’ point of view?
Authors: The presented results as well as other
unpublished results obtained by our group indicate that
chondrogenesis in pellet culture is generally superior to
that in scaffold culture, probably due to a higher cell
density, which is known to play a critical role in early stages
of cartilage formation. With the exception of one donor
(donor 5), where cells cultured in scaffold accumulated
more GAG as compared to those cultured in pellets, our
results overall reflect the trend outlined above. As a
quantitative confirmation of the qualitative observations,
we have now demonstrated a statistically significant
correlation (Pearson’s test, p<0.001) between the GAG/
DNA of scaffold-based constructs and of pellets generated
by cells of the corresponding donors and culture conditions.
Due to the relevance of the raised issue, the result has now
been introduced in the text (penultimate paragraph of
Results section). Based on our findings, we ultimately do
feel that it is possible to identify markers of chondrogenic
capacity which are valid across different in vitro model
systems.
S. Grad: It is surprising that there is no difference in cell
proliferation among the different serum groups. This may
lead to the conclusion that the growth factor supplements
added mainly account for the cell growth and that even
less serum or, alternatively, serum-free conditions would
result in similar proliferation rates. In addition, the finding
that a lower percentage of serum, i.e. of undefined
components, results in less variation in the outcome
suggests that autologous serum may affect the cells either
positively or negatively during expansion. Several studies
have shown the feasibility of serum-free conditions for
culture and expansion of human chondrocytes. Were
serum-free media also taken into consideration?
Authors: The Reviewer is absolutely correct in
highlighting that in our system the presence of growth
factors plays a critical role, likely larger than the
concentration of serum. This is also in line with a recent
publication from our group, specifically addressing the
raised issue (Francioli et al., 2007; text reference).
Regarding the use of serum free medium for the culture
of chondrocytes, it is true that several studies have proved
the feasibility of the concept, but some aspects are not yet
fully sorted out. In particular, the initial phase of
chondrocyte adhesion critically requires serum or serum
components, and the process of cell differentiation in 3D
scaffolds – likely because of the limited initial cell density
– hardly proceeds in the absence of serum. In our direct
experience, the development of a completely serum free
system for the engineering of cartilage tissues using human
chondrocytes remains a challenge.
M. Stoddart: why did the authors use TGFβ1 in pellets
but TGFβ3 in scaffolds?
Authors: For the differentiation in pellets and in scaffolds
we decided to use culture media established in previous
studies, respectively Tay et al. (2004; text reference) and
Farhadi et al. (2006; text reference). As a matter of fact,
the media formulations differ not only in the TGFβ
isoforms, but also in many other components (e.g., absence
or presence of serum). This was done on purpose, in order
to confirm the result using two diverse model systems,
and thus demonstrating that the outcome is not strictly
dependent on a specific medium composition.
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M. Stoddart: Normally an increase in serum concentration
is associated with an increase in final GAG content,
whereas in this work that does not seem to be the case.
Can you offer any suggestions as to why 2% autologous
serum results in the same GAG/DNA as 10% autologous
serum?
Authors: The literature in this field is quite controversial;
therefore it is not really obvious whether a higher
percentage of serum during the 3D culture of chondrocytes
is associated with an enhanced extent of chondrogenesis.
Indeed, some groups claim that absence of serum in high
density cultures supports more efficient chondrocyte
redifferentiation. Moreover, it must be highlighted that in
our experiments the effect of using different percentages
of serum, at least during the expansion phase, is masked
by the use of growth factors in the medium, which – as
mentioned in the discussion with S. Grad – apparently
reduce chondrocyte dependence from serum.
